Clinical Trial Update: A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicates a phase 2/3 study of danicamtiv for symptomatic genetic dilated cardiomyopathy is actively recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Genetic Dilated Cardiomyopathy

Drugs mentioned

• Danicamtiv (Danicamtiv)

Snippet

Sponsor: Kardigan, Inc. | Conditions: Symptomatic Genetic Dilated Cardiomyopathy | Phase 2, Phase 3 | Status: RECRUITING